BONE TISSUE FUNCTION AND STRUCTURE UNDER NORMAL AND PATHOLOGICAL CONDITIONS. MESSAGE I
Abstract
In the first part of the review, we discussed questions of bone tissue structural organization, Wnt-proteins function, bone morphogenic proteins, preosteoblast to osteoblast differentiation processes, synthetic function of osteoblasts and osteoblast importance in the regulation of osteoclast function.
About the Authors
A. V. Smirnov
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
A. Sh. Rumyantsev
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
References
1. Clarke B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol. 2008; 3 Suppl 3: S131-139
2. Quarles L.D. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest. 2008; 118(12): 3820-3828
3. Fukumato S., Martin T.J. Bone as an endocrine organ. Trends Endocrinol Metab. 2009; 20(5): 230-236
4. Хэм А., Кормак Д. Гистология. Т. 1 М.: Мир, 1982; 1360
5. Ревелл П.А. Патология кости. М.: Медицина, 1993; 368
6. Manolagas S.C. Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis. Endocr Rev. 2000; 21(2): 115-137
7. Krishnan V., Bryant H.U., Macdougald O.A. Regulation of bone mass by Wnt signaling. J Clin Invest. 2006; 116(5): 1202-1209.
8. Liu F., Kohlmeier S., Wang C.Y. Wnt signaling and skeletal development. Cell Signal. 2008; 20(6): 999-1009
9. Caetano-Lopes J., Canhăo H., Fonseca J.E. Osteoblasts and bone formation. Acta Reumatol Port. 2007; 32(2): 103-110
10. Westendorf J.J., Kahler R.A., Schroeder T.M. Wnt signaling: in osteoblasts and bone diseases. Gene. 2004; 341: 19-39
11. Cadigan K.M., Liu Y.I. Wnt signaling: complexity at the surface. J Cell Sci. 2006; 119(Pt 3): 395-402
12. Stains J.P., Civitelli R. Genomic approaches to identifying transcriptional regulators of osteoblast differentiation. Genone Biol. 2003; 4(7): 222
13. Krane S.M. Identifying genes that regulate bone remodeling as potential therapeutic targets. J Exp Med. 2005: 201(6): 841-843
14. Harada S., Rodan G.A. Control of osteoblast function and regulation of bone mass. Nature. 2003; 423(6937): 349-355
15. Ducy P, Schinke T., Karsenty G. The osteoblast: a sophisticated fibroblast under central surveillance. Science. 2000; 289(5484): 1501-4
16. Mackie E.J. Osteoblasts: novel roles in orchestration of skeletal architecture. Int J Biochem Cell Biol. 2003; 35(9): 1301-1305
17. Mundios S., Otto F., Mundios C. et al. Mutations involving the transcription factor CBFA1 cause cleidocranial dysplasia. Cell. 89(5): 773-779
18. Karsenty G. Minireview: transcriptional control of osteoblast differentiation. Endocrinology 2001; 142(7): 2731-2733
19. Koga T., Inui M., Inoue K. et al. Costimulatory signal mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature. 2004; 428(6984): 758-763
20. Смирнов А.В. Лечение гломерулопатий циклоспорином: правильный подход с неверным обоснованием. Нефрология. 2010; 14: 9-22
21. Day T.F. Guo X., Garrett-Beal L., Yang Y. Wnt/beta-catenin signaling in mesenchymal progenitors controls osteoblast and chondrocyte differentiation during vertebrate skeletogenesis. Dev Cell. 2005; 8(5): 739-750
22. Boyden L.M., Mao J., Belsky J. et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002; 346(20): 1513-1521
23. Little R.D., Carulli J.P., Del Mastro R.G. et al. A mutation in the LDL-receptor-related protein 5 gene results in the autosomal dominant high-bone-mass trait. Am J Hum Genet. 2002; 70(1): 11-19
24. Issack P.S., Helfet D.L., Lane J.M. Role of Wnt signaling in bone remodeling and repair. HSS J. 2008; 4(1): 66-70
25. Winkler D.G., Sutherland M.K., Geoghegan J.C. et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J. 2003; 22(23): 6267-6276
26. ten Dijke P., Krause C., de Gorter D.J. et al. Osteocyte-derived sclerostin inhibits bone formation: ist role in bone morphogenetic protein and Wnt signaling. J Bone Joint Surg Am. 2008; 90 Suppl 1: 31-35
27. Li J., Sarosi I., Cattley R.C. et al. Dkk1-mediated inhibition of Wnt signaling in bone results in osteopenia. Bone. 2006; 39(4): 754-766
28. Qiang Y.W., Barlogie B., Rudikoff S., Shaughnessy J.D. Jr. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma. Bone. 2008; 42(4): 669-680
29. Urist M.R. Bone: formation by autoinduction. Science. 1965; 150(698): 893-899
30. Chen D., Zhao M., Mundy G.R. Bone morphogenetic proteins. Growth Factors. 2004; 22(4): 233-241
31. Cao X., Chen D. The BMP signaling and vivo bone formation. Gene. 2005; 357(1): 1-8
32. Otsuka F. Multiple endocrine regulation by bone morphogenetic protein system. Endocr. J. 2010; 57(1): 3-14
33. Otani H., Otsuka F., Inagaki K. et al. Aldosterone breakthrough caused by chronic blockage of angiotensin II type 1 receptors in human adrenocortical cells: possible involvement of bone morphogenetic protein-6 actions. Endocrinology. 2008; 149(6): 2816-2825
34. Otani H., Otsuka F., Inagaki K. et al. Roles of bone morphogenetic protein-6 in aldosterone regulation by adrenocortical cells. Acta Med Okayama. 2010; 64(4): 213-218
35. Goto J., Otsuka F., Yamashita M. et al. Enhancement of aldosterone-induced catecholamine production by bone morphogenetic protein-4 through activating Rho and SAPK/JNK pathway in adrenomedullar cells. Am J Physiol Endocrinol Metab. 2009; 296(4): E904-916
36. Takeda M., Otsuka F., Nakamura K. et al. Characterization of the bone morphogenetic protein (BMP) system in human pulmonary arterial smooth muscle cells isolated from a sporadic case of primary pulmonary hypertension: roles of BMP type IB receptor (activin receptor-like kinase-6) in the mitotic action. Endocrinology. 2004; 145(9): 4344-4354
37. Wang S., Chen Q., Simon T.C. et al. Bone morphogenic protein-7 (BMP-7), a novel therapy for diabetic nephropathy. Kidney Int. 2003; 63(6): 2037-2049
38. Morrissey J., Hruska K., Guo G. et al. Bone morphogenetic protein-7 improves renal fibrosis and accelerates the return of renal function. J Am Soc Nephrol. 2002; 13 Suppl 1: S14-21
39. Abe E., Yamamoto M., Taguchi Y. et al. Essential reguirement of BMPs-2/4 for both osteoblast and osteoclast formation in murine bone marrow cultures from adult mice: antagonism by noggin. J Bone Miner Res. 2000; 15(4): 663-673
40. Cheng H., Jiang W., Phillips F.M. et al. Osteogenic activity of the fourteen types of human bone morphogenetic proteins (BMPs). J Bone Joint Surg Am. 2003; 85-A(8): 1544-1552
41. Fiedler J., Röderer G., Günther K.P., Brenner R.E. BMP-2, BMP-4 and PDGF-bb stimulate chemotactic migration of primary human mesenchymal progenitor cells. J Cell Biochem. 2002; 87(3): 305-312
42. Canalis E., Giustina A., Bilezikian J.P. Mechanisms of anabolic therapies for asteoporosis. N Engl J Med. 2007; 357(9): 905-916
43. Ducy P., Zhang R., Geoffroy V. et al. Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation. Cell. 1997; 89(5): 747-754
44. Sakou T. Bone morphogenetic proteins: from basic studies to clinical approaches. Bone. 1998; 22(6): 591-603
45. Nordsletten L., Madsen J.E. The effect of bone morphogenetic proteins in fracture healing. Scand J Surg. 2006; 95(2): 91-94
46. Herrington J., Carter-Su C. Signaling pathways activated by the growth hormone receptor. Trends Endocrinol Metab. 2001; 12(6): 252-257
47. Canalis E. The fate of circulating osteoblasts. N Engl J Med. 2005; 352(19): 2014-2016
48. Zhao G., Monier-Faugere M.C., Langub M.C. et al. Targeted overexpression of insulin-like growth factor I to osteoblasts of transgenic mice: increased trabecular bone volume without increased osteoblast proliferation. Endocrinology. 2000; 141(7): 2674-2682
49. Ogata N., Chikazu D., Kubota N. et al. Insulin receptor substrate-1 in osteoblast is indispensable for maintaining bone turnover. J Clin Invest. 2000; 105(7): 935-943
50. Zhang M., Xuan S., Bouxsein M.L. et al. Osteoblast-specific knockout of the insulin- like growth factor (IGF) receptor gene reveals an essential role of IGF signaling in bone matrix mineralization. J Biol Chen. 2002; 277(46): 44005-44012
51. Lombardi G., Di Somma C., Vuolo L. et al. Role of IGF-I on PTH effects on bone. J Endocrinol Invest. 2010; 33(7 Suppl): 22-26
52. Dobnig H., Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology. 1995; 136(8): 3632-3638
53. Poole K.E., Reeve J. Parathyroid hormone - a bone anabolic and catabolic agent. Curr Opin Pharmacol. 2005; 5(6): 612-617
54. Jilka R.L. Molecular and cellular mechanisms of the anabolic effect of intermittent PTH. Bone. 2007; 40(6): 1434-1446
55. Kramer I., Keller H., Leupin O., Kneissel M. Does osteocytic SOST suppression mediate PTH bone anabolism? Trends Endocrinol Metab. 2010; 21(4); 237-244
56. Schnoke M., Midura S.B., Midura R.J. Parathyroid hormone suppresses osteoblast apoptosis by augmenting DNA repair. Bone.2009; 45(3): 590-602
57. Sabbieti M.G., Agas D., Xiao L. et al. Endogenous FGF-2 is critically important in PTH anabolic effects on bone. J Cell Physiol. 2009; 219(1): 143-151
58. Qin L., Tamasi J., Raggatt L. et al. Amphiregulin is a novel growth factor involved in normal bone development and in the cellular response to parathyroid hormone stimulation. J Biol Chem. 2005; 280(5): 3974-3981
59. Guo J., Liu M., Yang D. et al. Suppression of Wnt signaling by Dkk1 attenuates PTH-mediated stromal cell response and new bone formation. Cell Metab. 2010; 11(2): 161-171
60. Cejka D., Herberth J., Branscum A.J. et al. Sclerostin and Dickkopf-1 in Renal Osteodystrophy. Clin J Am Nephrol. 2011; 6(4): 877-882
61. Yamaguchi M., Ogata N., Shinoda Y et al. Insulin receptor substrate-1 is reguired for bone anabolic function of parathyroid hormone in mice. Endocrinology. 2005; 146(6): 2620-2628
62. Chen P., Miller P.D., Delmas P.D. et al. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006; 21(11): 1785-1790
63. Rubin M.R., Bilezikian J.P. The anabolic effects of parathyroid hormone therapy. Clin Geriatr Med. 2003; 19(2): 415-432
64. Veis A. Mineral-matrix interactions in bone and dentin. J Bone Miner Res. 1993; 8 Suppl 2: S493-497
65. Bernards M.T., Qin C., Ratner B.D., Jiang s. Adhesion of MC3T3-E1 cells to bone sialoprotein and bone osteopontin specifically bound to collagen I. J Biomed Mater Res A. 2008; 86(3): 779-787
66. Seibel M.J. Biochemical markers of bone turnover: part I: biochemistry and variability. Clin Biochem Rev. 2005; 26(4): 97-122
67. Chenu C., Colucci S., Grano M. et al. Osteocalcin induces chemotaxis, secretion of matrix proteins, and calcium- mediated intracellular signaling in human osteoclast- like cells. J Cell Biol. 1994; 127(4): 1149-1158
68. Brown J.P., Delmas P.D., Malaval L. et al. Serum bone Glaprotein: a specific marker for bone formation in postmenopausal osteoporosis. Lancet. 1984; 1(8386): 1091-1093
69. Cloos P.A., Christgau S. Characterization of aged osteocalcin fragments derived from bone resorption. Clin Lab. 2004; 50(9-10): 585-598
70. Yamada S., Inaba M., Kurajoh M. et al. Utility of serum tartrate-resistant acid phosphatase (TRACP5b) as a bone resorption marker in patients with chronic kidney disease: independence from renal dysfunction. Clin Endocrinol (Oxf). 2008; 69(2): 189-196
71. Bacchetta J., Boutroy S., Guebre-Egziabher F. et al. The relationship between adipokines, osteocalcin and bone guality in chronic kidney disease. Nephrol Dial Transplant. 2009; 24(10): 3120-3125
72. Kim Y.S., Paik I.Y., Rhie Y.J., Suh S.H. Integrative physiology: defined novel metabolic roles of osteocalcin. J Korean Med Sci. 2010; 25(7): 985-991
73. Ferron M., Hinoi E., Karsenty G., Ducy P. Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA. 2008; 105(13): 5266-5270
74. Singer F.R., Eyre D.R. Using biochemical markers of bone turnover in clinical practice. Cleve Clin J Med.2008; 75(10): 739-750
75. Langlois M.R., Delanghe J.R., Kaufman J.M. et al. Posttranslational heterogeneity of bone alkaline phosphatase in metabolic bone disease. Eur J Clin Chem Clin Biochem. 1994; 32(9): 675-680
76. Orimo H. The mechanism of miniralisation and the role of alkaline phosphatase in health and disease. J Nippon Med Sch. 2010; 77(1): 4-12
77. Baim S., Miller P.D. Assessing the clinical utility of serum CTX in postmenopausal osteoporosis and its use in predicting risk of osteonecrosis of the jaw. J Bone Miner Res. 2009; 24(4): 561-574
78. Robins S.P. Collagen crosslinks in metabolic bone disease. Acta Orthop Scand Suppl. 1995; 266: 171-175
79. Martin E., Shapiro J.R. Osteogenesis imperfecta: epidemiology and pathophysiology. Curr Osteoporos Rep. 2007; 5(3): 91-97
80. Gal-Moscovici A., Sprague S.M. Role of bone biopsy in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2008; 3 Suppl 3: S170-174
81. Goodman W.G. O’Connor J. Aluminum alters calcium influx and efflux from bone in vitro. Kidney Int. 1991; 39(4): 602-607
82. Hodgson S.F. Skeletal remodeling and renal osteodystrophy. Semin Nephrol. 1986; 6(1): 42-55
83. Kidd P.M. Vitamins D and K as pleiotropic nutrients: clinical importance to the skeletal and cardiovascular systems and preliminary evidence for synergy. Altern Med Rev. 2010; 15(3): 199-222
84. Weiner S., Sagi I., Addadi L. Structular biology. Choosing the crystallization path less traveled. Science. 2005; 309(5737): 1027-1028
85. Anderson H.C. Matrix vesicles and calcification. Curr Rheumatol Rep.2003; 5(3): 222-226
86. Boyce B.F., Xing L. Biology of RANK, RANKL, and osteoprotegerin. Arthritis Res Ther. 2007; 9 Suppl 1: S1
87. Lacey D.L., Timms E., Tan H.L. et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93(2): 165-176
88. Onyia J.E., Miles R.R., Yang X. et al. In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. J Bone Miner Res. 2000; 15(5): 863-871
89. Huang J.C., Sakata T., Pfleger L.L. et al. PTH differentially regulates expression of RANKL and OPG.J Bone Miner Res. 2004; 19(2): 235-244
90. Avbersek-Luznik I., Balon B.P., Rus I., Marc J. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis. Nephrol Dial Transplant. 2005; 20(3): 566-570
91. Coen G., Ballanti P., Balducci A. et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant. 2002; 17(2): 233-238
92. Moe S.M., Drüeke T. Improving global outcomes in mineral and bone disorders. Clin J Am Soc Nephrol. 2008; 3 Suppl 3: S127-130
93. Couttenye M.M., D’Haese P.C., Verschoren W.J. et al. Low bone turnover in patients with renal failure. Kidney Int Suppl. 1999; 73: S70-76
94. Iwasaki- Ishizuka Y., Yamato H., Nii-Kono T. et al. Down-regulation of parathyroid hormone receptor gene expression and osteoblastic dysfunction associated with skeletal resistance to parathyroid hormone in a rat model of renal failure with low turnover bone. Nephrol Dial Transplant. 2005; 20(9): 1904-1911
95. Picton M.L., Moore P.R., Mawer E.B. et al. Down-regulation of human osteoblast PTH/PTHrP receptor mRNA in end-stage renal failure. Kidney Int. 2000; 58(4): 1440-1449
96. Adams J.S., Hewison M. Update in vitamin D. J Clin Endocrinol Metab. 2010: 95(2): 471-478
97. Malaponte G., Bevelacgua V., Fatuzzo P. et al. IL-1beta, TNF-alpha and IL-6 release from monocytes in haemodialysis patients in relation to dialytic age. Nephrol Dial Transplant. 2002; 17(11): 1964-1970
98. Duarte M.E., Carvalho E.F., Cruz E.A. et al. Cytokine accumulation in osteitis fibrosa of renal osteodystrophy. Braz J Med Biol Res. 2002; 35(1): 25-29
99. Santos F.R., Moyses R.M., Montenegro F.L. et al. IL-1beta, TNF-alpha, TGF-beta, and bFGF expression in bone biopsies before and after parathyroidectomy. Kidney Int. 2003; 63(3): 899-907
100. Greenfield E.M., Shaw S.M., Gornik S.A., Banks M.A. Adenyl cyclase and interleukin 6 are downstream effectors of parathyroid hormone resulting in stimulation of bone resorption. J Clin Invest. 1995; 96(3): 1238-1244
101. Groopman J.E., Molina J.M., Scadden D.T. Hematopoietic growth factors. Biology and clinical applications. N Engl J Med. 1989; 321(21): 1449-1459
102. Schett G., Stach C., Zwerina J. et al. How antirheumatic drugs protect joints from damage in rheumatoid arthritis. Arthritis Rheum. 2008; 58(10): 2936-2948
103. Freundlich M., Alonzo E., Bellorin-Font E., Weisinger J.R. Increased osteoblastic activity and expression of receptor activator of NF-kappaB ligand in nonuremic nephrotic syndrome. J Am Soc Nephrol. 2005; 16(7): 2198-2204
104. Sweiss N.J., Hushaw L.L. Biologic agents for rheumatoid arthritis: 2008 and beyond. J Infus Nurs. 2009; 32(1 Suppl): S4-17
105. Wada T., Nakashima T., Hiroshi N., Penninger J.M. RANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med. 2006; 12(1): 17-25
106. Cummings S.R., San Martin J., McClung M.R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361(8): 756-765
107. Fill S., Karalaki M., Schaller B. Therapeutic implications of osteoprotegerin. Cancer Cell Int. 2009; 9: 26
108. Гельцер Б.И., Кочеткова Е.А., Семисотова Е.Ф. и др. Атеросклероз и остеопороз: общий взгляд на проблему. Тер. архив. 2006; 78 (10): 81-85
109. Pritzker L.B., Scatena M., Giachelli C.M. The role of osteoprotegerin and tumor necrosis factor-related apoptosis-inducing ligand in human microvascular endothelial cell survival. Mol Biol Cell. 2004; 15(6): 2834-2841
110. Venuraju S.M., Yerramasu A., Corder R., Lahiri F. Osteoprotegerin as a predictor of coronary artery disease and cardiovascular mortality and morbidity. J Am Coll Cardiol. 2010; 55(19): 2049-2061
111. Jono S., Ikari Y., Shioi A. et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106(10): 1192-1194
112. Kiechl S., Schett G., Wenning G. et al. Osteoprotegerin is a risk factor for progressive atherosclerosis and cardiovascular disease. Circulation. 2004; 109(18): 2175-2180
113. Avignon A., Sultan A., Piot C. et al. Osteoprotegerin: a novel independent marker for silent myocardial ischemia in asymptomatic diabetic patients. Diabetes Care. 2007; 30(11): 2934-2939
114. Omland T., Ueland T., Jansson A.M. et al. Circulating osteoprotegerin levels and long-term prognosis in patients with acute coronary syndromes. J Am Coll Cardiol. 2008; 51(6): 627-633
115. Morena M., Terrier N., Jaussent I. et al. Plasma osteoprotegerin is associated with mortality in hemodialysis patients. J Am Soc Nephrol. 2006; 17(1): 262-270
116. Hjelmesaeth J., Ueland T., Flyvbjerg A. et al. Early posttransplant serum osteoprotegerin levels predict long-term (8-year) patient survival and cardiovascular death in renal transplant patients. J Am Soc Nephrol. 2006; 17(6): 1746-1754
117. Sigrist M.K., Levin A., Er L., Mclntyre C.W. Elevated osteoprotegerin is associated with all-cause mortality in CKD stage and 5 patients in addition to vascular calcification. Nephrol Dial Transplant. 2009; 24(10): 3157-3162
118. Bennett B.J., Scatena M., Kirk E.A. et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol. 2006; 26(9): 2117-2124
119. Jono S., Ikari Y., Shioi A. et al. Serum osteoprotegerin levels are associated with the presence and severity of coronary artery disease. Circulation. 2002; 106(10): 1192-1194
120. Anand D.V., Lahiri A., Lim E. et al. The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects. J Am Coll Cardiol. 2006; 47(9): 1850-1857
121. Nitta K., Akiba T., Uchida K. et al. Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. Nephrol Dial Transplant. 2004; 19(7): 1886-1889
122. Morena M., Dupuy A.M., Jaussent I. et al. A cut-off value of plasma osteoprotegerin level may predict the presence of coronary artery calcifications in chronic kidney disease patients. Nephrol Dial Transplant. 2009; 24(11): 3389-3397
Review
For citations:
Smirnov A.V., Rumyantsev A.Sh. BONE TISSUE FUNCTION AND STRUCTURE UNDER NORMAL AND PATHOLOGICAL CONDITIONS. MESSAGE I. Nephrology (Saint-Petersburg). 2014;18(6):9-25. (In Russ.)
Views:
714
Email this article 